Literature DB >> 17331788

c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.

Xia Jiang1, Ying Hung Tsang, Qiang Yu.   

Abstract

Overexpression of the oncogene c-Myc sensitizes many apoptotic signals through the activation of mitochondrial apoptosis pathway. However, the underling mechanism has not been clearly defined. Here, we investigated the effect of c-Myc expression on histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)-induced apoptosis in rat fibroblast cells possessing various c-Myc levels. In Rat 1a cells overexpressing c-Myc, SAHA-induced enhanced the cell death response relative to the parental cells; whereas Rat 1a cells lacking c-Myc were refractory to SAHA treatment. We demonstrated that SAHA selectively induced the expression of pro-apoptotic BH3-only protein Bim, leading to Bax activation in c-Myc-expressing cells. Where c-Myc was absent, Bim, despite its induction by SAHA, failed to activate Bax and was unable to induce apoptosis. These results indicate that c-Myc is dispensable for Bim induction by SAHA, but is required for subsequent Bax activation. We further show that the expression levels of anti-apoptotic Bcl-2/Bcl2-xL were much elevated in Myc-null cells compared with the c-Myc-expressing cells; furthermore, depletion of Bcl-2/Bcl-xL in these cells restored the ability of SAHA to induce apoptosis by enhancing Bax activation. These data indicate that SAHA induces apoptosis through Bim-triggered Bax activation and that c-Myc regulates this process by modulating Bcl-2/Bcl-xL. Our results provide novel insight into the mechanism whereby Myc sensitizes the apoptotic signals; furthermore, our data suggest that cancer cells with deregulated Myc might be more sensitive to SAHA treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331788     DOI: 10.1016/j.biocel.2007.01.024

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  8 in total

1.  Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.

Authors:  Victoria L Luchenko; Thomas Litman; Arup R Chakraborty; Aaron Heffner; Christopher Devor; Julia Wilkerson; Wilfred Stein; Robert W Robey; Lois Bangiolo; David Levens; Susan E Bates
Journal:  Mol Oncol       Date:  2014-05-28       Impact factor: 6.603

2.  Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.

Authors:  Andelko Hrzenjak; Farid Moinfar; Marie-Luise Kremser; Bettina Strohmeier; Edgar Petru; Kurt Zatloukal; Helmut Denk
Journal:  Mol Cancer       Date:  2010-03-04       Impact factor: 27.401

3.  Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.

Authors:  Barbora Brodská; Petra Otevřelová; Aleš Holoubek
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

Review 4.  Histone deacetylase inhibitors: emerging mechanisms of resistance.

Authors:  Robert W Robey; Arup R Chakraborty; Agnes Basseville; Victoria Luchenko; Julian Bahr; Zhirong Zhan; Susan E Bates
Journal:  Mol Pharm       Date:  2011-10-07       Impact factor: 4.939

5.  Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.

Authors:  Todd M Pitts; Mark Morrow; Sara A Kaufman; John J Tentler; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

6.  Nickel compounds induce apoptosis in human bronchial epithelial Beas-2B cells by activation of c-Myc through ERK pathway.

Authors:  Qin Li; Ting-Chung Suen; Hong Sun; Adriana Arita; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2008-12-16       Impact factor: 4.219

7.  Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Authors:  Laleh Amiri-Kordestani; Victoria Luchenko; Cody J Peer; Kambiz Ghafourian; James Reynolds; Deb Draper; Robin Frye; Sue Woo; David Venzon; John Wright; Monica Skarulis; William D Figg; Tito Fojo; Susan E Bates; Richard L Piekarz
Journal:  Clin Cancer Res       Date:  2013-06-11       Impact factor: 12.531

8.  Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.

Authors:  David Perera; Ashok R Venkitaraman
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.